IHealthScreen Receives FDA Approval for AI-Powered Diabetic Retinopathy Screening Solution 'iPredict-DR'
A New Milestone in AI-Based Ophthalmic Screening
IHealthScreen Inc., a medical technology company based in New York, USA, has obtained 510(k) clearance (approval number K253704) from the U.S. Food and Drug Administration (FDA) for its in-house developed, artificial intelligence (AI)-based medical device software (Software as a Medical Device, SaMD) called 'iPredict-DR'. This approval marks a regulatory turning point, enabling general primary care settings, not just ophthalmologists, to utilize images of the retina captured with the iCare DRSplus camera to instantly analyze a patient's retinal condition. Specifically, it establishes the legal basis for AI-based screening of undiagnosed adult diabetic patients at risk of moderate or higher stages of diabetic retinopathy, paving the way for full-scale commercial sales.
High Clinical Accuracy and the Value of Early Diagnosis
iPredict-DR has demonstrated excellent diagnostic performance in large-scale clinical validation studies, achieving a sensitivity of 97.0% and a specificity of 96.3% in detecting diabetic retinopathy. Diabetic retinopathy, one of the most serious complications of diabetes, can lead to blindness if left untreated due to the lack of early symptoms. The introduction of this AI-based diagnostic tool is expected to dramatically increase the rate of early detection. Patients will be able to undergo a rapid screening process, which takes less than a minute, before receiving expensive, detailed ophthalmological examinations, significantly improving access to care and preventing the risk of blindness.
Revolutionizing Workflows in Primary Care Settings
This platform is non-invasive and designed to be easily operated by nurses or other healthcare personnel with limited specialized knowledge, maximizing efficiency in clinical settings. In the U.S. healthcare system, which faces a severe shortage of ophthalmologists, this system will contribute to establishing a system in which patients can receive initial care and simultaneously have their risk of blindness assessed. This will enable faster referrals to specialists, resolve bottlenecks, and lead to economic benefits by reducing overall diabetes management costs nationwide.
Exploding Medical AI Market and the Race for Market Share
The global diabetic retinopathy market is estimated at approximately $10.5 billion (USD) by 2026, and the AI-based screening market is also rapidly expanding, reaching approximately $190 million in the U.S. alone by 2025. As a result, competition for market share is expected to intensify with established players such as Digital Diagnostics' LumineticsCore (formerly IDx-DR, approved in 2018) and Eyenuk's EyeArt (approved in 2020). IHealthScreen plans to leverage this approval to expand its pipeline into the diagnosis of age-related macular degeneration (AMD), glaucoma, and cardiovascular disease risk, further strengthening its market competitiveness.
The FDA 510(k) clearance obtained by IHealthScreen's iPredict-DR recognizes the clinical utility of AI-based software (SaMD) in the diabetic retinopathy market, which is projected to reach $10.5 billion by 2026. In the short term, with its high accuracy of 97.0% sensitivity and 96.3% specificity, it will rapidly penetrate primary care settings, creating intense competition with established players such as Digital Diagnostics' LumineticsCore (approved in 2018) and Eyenuk's EyeArt (approved in 2020). In the medium to long term, this diagnostic platform is expected to become an integral part of the workflow in primary care settings, improving the efficiency of early screening for diabetic complications and reducing healthcare costs. Furthermore, it will increase the likelihood of subsequent approvals for the company's AI pipeline for the diagnosis of age-related macular degeneration (AMD) and glaucoma, diversifying its portfolio and boosting its corporate value.